Home » FDA » Page 24

Tag Archives: FDA

Here They Are: Dalbavancin and Oritavancin – The New Long-Acting Lipoglycopeptides

Posted on by — No Comments ↓

The development history of glycopeptide drugs is anything but normal.  Daptomycin (Cubicin®) was abandoned by Lilly but resurrected by Francis Tally at Cubist by adjusting the dosing schedule to once daily and careful uptitration.  The drug did superbly in a landmark endocarditis trial and everything looked rosy.  Then we learned Continue reading Here They Are: Dalbavancin and Oritavancin – The New Long-Acting Lipoglycopeptides→

And the Results are …Pending

Posted on by — No Comments ↓

The website “ClinicalTrials.gov” has become the first stop for many of us who need to check on trial activity of a particular drug.  All larger human Phase 2 – 4 trials are listed there in quite some detail.  While companies sometimes shy away from publishing full entry criteria or primary Continue reading And the Results are …Pending→

The Breakpoint Dilemma

Posted on by — 1 Comment ↓

As antibiotic resistance increases over the years, originally established susceptibility breakpoints (S-I-R) are becoming less relevant.   This ‘creep’ towards higher MICs over time is a unique but well-known feature of antimicrobials ultimately making these drugs obsolete. In the past, FDA and CLSI did not bother to update breakpoints in Continue reading The Breakpoint Dilemma→